• 10 April 2018

    Mixed results for Merck and Incyte cancer drug trials

    Incyte Corporation and Merck have announced that they are stopping trials of Incyte’s epacadostat in combination with Merck’s Keytruda in patients with unresectable or metastatic melanoma after an external Data...